Pizzas, pasta… Nestlé launches products for users of obesity medications

Pizzas, pasta… Nestlé launches products for users of obesity medications
Pizzas, pasta… Nestlé launches products for users of obesity medications

The food giant will launch a brand in the United States called Vital Pursuit aimed at users of GLP-1 analogs, used to manage type 2 diabetes and treat obesity.

The food giant Nestlé announced on Tuesday the launch in the United States of a range of products, including pizzas and pastas, for users of anti-obesity drugs, such as Wegovy, which are all the rage on social networks .

The group – owner, among others, of Nespresso coffee pods and KitKat chocolate bars – will launch a brand called Vital Pursuit aimed at users of GLP-1 analogues, used to manage type 2 diabetes and treat obesity, indicates – he said in a press release.

Obesity: revolutionary drugs – 04/03

This new line of products – which includes pizzas, pastas and sandwiches at a suggested price of $4.99 or less – is intended to support users of these medications by offering them products rich in protein, fiber and nutrients to meet the needs. dietary deficiencies, with portions adapted to an appetite that decreases with the use of these treatments.

“One in 60 adults will be prescribed a GLP-1 drug in 2023,” underlines the Swiss group, which cites figures from the American Pharmacists Association. And according to projections from the American bank JP Morgan, the number of users could reach 30 million in the United States by 2030, or 9% of the population, the press release added.

Stock shortages

GLP-1 analogs (short for glugaco-like peptide 1) mimic a hormone secreted by the intestines that stimulates insulin secretion and suppresses appetite by providing a feeling of fullness. Among the best known are the drug Ozempic, against type 2 diabetes, and the drug Wegovy, against obesity, both manufactured by the Danish laboratory Novo Nordisk.

These treatments have received a lot of attention for having become all the rage on social networks due to their weight-loss properties to the point of leading to stock-outs. In the financial community, the craze for these treatments has also raised questions about the growth potential of manufacturers of confectionery and products that are too fatty, too sweet or too salty, who risk seeing their customer base shrink.

During its general meeting in mid-April, Nestlé was the subject of strong criticism from a group of investors who had demanded a vote to force the group to adopt stricter objectives concerning the share of food healthy in its turnover. This vote was, however, rejected by 87.88% of the votes.

Nestlé CEO Mark Schneider spoke about these drugs and explained that the group intended to offer products that help take into account the nutritional gaps that can result, by marketing foods containing vitamins, minerals and supplements to fill the deficiencies. This new brand will arrive on the shelves during the fourth quarter, specifies the press release from the Nestlé branch in the United States.

-

-

PREV Six-day-old newborn thrown from car seat by two careless people
NEXT Corentin Moutet puts on a show and qualifies for the round of 16